Therapeutic Products

Touchlight’s novel dbDNA vector offers advantages over both plasmid and other DNA formats.

The doggybone™ (dbDNA™) vector offers complete design control, with the ability to encode very large and unstable sequences. The vector offers safety benefits by eliminating the bacterial sequences of plasmid. The enzymatic process enables industrial scalability of DNA, and enables robust, rapid and controllable production of any drug.

At Touchlight, we are leveraging the doggybone platform to develop medicines in collaboration with scientific leaders in areas of high unmet need where dbDNA may offer unique or improved therapies.


Touchlight product pipeline

TGL-100 TGL-100

Head and Neck Squamous Cell Carcinoma; Other solid tumour

TGL-210 TGL-210

COVID-19 (SARS-CoV-2)

Multiple indications

TOUCHLIGHT COLLABORATIONS

Our ambition is for our technology to underpin the development and commercialisation of the next generation of DNA products.

Contact us about collaboration and partnering